View Future GrowthKBIO LABS 과거 순이익 실적과거 기준 점검 0/6KBIO LABS은 연평균 21.7%의 비율로 수입이 증가해 온 반면, Consumer Durables 산업은 연평균 2.1%의 비율로 증가했습니다. 매출은 연평균 40.1%의 비율로 증가했습니다.핵심 정보21.70%순이익 성장률33.30%주당순이익(EPS) 성장률Consumer Durables 산업 성장률8.99%매출 성장률40.08%자기자본이익률-4.93%순이익률-3.66%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...모든 업데이트 보기Recent updates공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.분석 기사 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공시 • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea분석 기사 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).분석 기사 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.공시 • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.공시 • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.공시 • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.공시 • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.공시 • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.매출 및 비용 세부 내역KBIO LABS가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A038530 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 2587,312-3,2009,4231,32130 Sep 2583,849-12,47510,8491,39630 Jun 2582,789-12,08810,6441,35631 Mar 2581,012-7,01110,5051,15331 Dec 2476,514-6,79110,3991,13230 Sep 2458,3181,5936,91279930 Jun 2448,288-1935,76054131 Mar 2435,821-10,7114,88426631 Dec 2327,325-11,8173,674031 Mar 2329,974-4,9882,183031 Dec 2231,129-7,0152,678030 Sep 2230,729-11,7926,399030 Jun 2223,325-17,4796,551031 Mar 2216,435-12,2626,801031 Dec 218,722-16,5856,311030 Sep 196,381-8,7886,655030 Jun 192,853-7,1995,950031 Mar 194,153-5,5925,154031 Dec 185,708-4,3805,301030 Sep 182,446-9014,275030 Jun 184,293-4193,530031 Dec 175,031-9651,762031 Dec 1518,635-10,2167,7997630 Sep 1519,097-7,5034,75717130 Jun 1520,955-9,1145,106171양질의 수익: A038530 은(는) 현재 수익성이 없습니다.이익 마진 증가: A038530는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A038530는 수익성이 없지만 지난 5년 동안 연평균 21.7%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A038530의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A038530은 수익성이 없어 지난 해 수익 성장률을 Consumer Durables 업계(-14.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A038530는 현재 수익성이 없으므로 자본 수익률이 음수(-4.93%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-durables 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:47종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KBIO LABS Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...
공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea
분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).
분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).
Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.
분석 기사 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공시 • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea
분석 기사 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).
분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).
분석 기사 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).
Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.
공시 • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.
공시 • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.
Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.
공시 • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.
Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.
공시 • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
공시 • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.